Cara Therapeutics, Inc. (NASDAQ:CARA) Receives Average Rating of “Hold” from Analysts

Shares of Cara Therapeutics, Inc. (NASDAQ:CARA) have earned a consensus recommendation of “Hold” from the five analysts that are presently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a hold recommendation. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $27.84.

Separately, StockNews.com began coverage on Cara Therapeutics in a report on Wednesday, January 8th. They issued a “sell” rating on the stock.

Cara Therapeutics Stock Performance

Shares of NASDAQ CARA opened at $5.01 on Friday. Cara Therapeutics has a 52-week low of $2.71 and a 52-week high of $13.80. The firm has a market capitalization of $22.90 million, a price-to-earnings ratio of -0.24 and a beta of 0.51. The stock has a 50 day moving average price of $4.39 and a 200 day moving average price of $3.98.

Institutional Investors Weigh In On Cara Therapeutics

Large investors have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new stake in Cara Therapeutics during the 3rd quarter worth about $29,000. FMR LLC raised its stake in shares of Cara Therapeutics by 18.5% in the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 32,789 shares during the last quarter. Finally, Disciplined Growth Investors Inc. MN lifted its holdings in shares of Cara Therapeutics by 6.6% during the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 120,660 shares during the period. 44.66% of the stock is owned by hedge funds and other institutional investors.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.